Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus:: Implications for the safety of lentiviral vectors

被引:120
作者
Wagner, R
Graf, M
Bieler, K
Wolf, H
Grunwald, T
Foley, P
Überla, K
机构
[1] Univ Regensburg, Inst Med Mikrobiol & Hyg, D-93053 Regensburg, Germany
[2] Univ Leipzig, Inst Virol, D-04103 Leipzig, Germany
关键词
D O I
10.1089/104303400750038507
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The safety of lentiviral vectors for clinical applications is still a major concern. The gag-pol expression plasmids and the lentiviral vectors used in previous studies contain homologous regions, which constitute a risk for recombination events. Synthetic gag-pol genes of human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV) were therefore constructed, in which the codon usage was optimized for expression in human cells without altering the amino acid sequences. The synthetic gag-pol genes allowed efficient expression of these genes in the absence of Rev and the 5' untranslated leader region. Both the HIV-1 and the SIV synthetic gag-pol expression plasmids could mediate transduction of an SIV vector into nondividing human cells with titers of about 10(6) transducing units/ml. Similar titers were obtained with a four-plasmid vector-packaging system based on HIV-1. Using a biological assay, homologous recombination events between the synthetic gag-pol expression plasmids and an SIV vector were undetectable and in comparison with a previously used gag-pol expression plasmid at least approximately 100-fold less frequent. By eliminating regions of homology and sequences involved in packaging, synthetic gag-pol genes should improve the safety profile of lentiviral vectors.
引用
收藏
页码:2403 / 2413
页数:11
相关论文
共 42 条
[1]   Human immunodeficiency virus type 2 lentivirus vectors for gene transfer: Expression and potential for helper virus-free packaging [J].
Arya, SK ;
Zamani, M ;
Kundra, P .
HUMAN GENE THERAPY, 1998, 9 (09) :1371-1380
[2]  
Blomer U, 1997, J VIROL, V71, P6641
[3]   Stable transduction of quiescent CD34+CD38- human hematopoietic cells by HIV-1-based lentiviral vectors [J].
Case, SS ;
Price, MA ;
Jordan, CT ;
Yu, XJ ;
Wang, LJ ;
Bauer, G ;
Haas, DL ;
Xu, DK ;
Stripecke, R ;
Naldini, L ;
Kohn, DB ;
Crooks, GM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (06) :2988-2993
[4]   Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system [J].
Chang, LJ ;
Urlacher, V ;
Iwakuma, T ;
Cui, Y ;
Zucali, J .
GENE THERAPY, 1999, 6 (05) :715-728
[5]  
FLETCHER TMI, 1997, EMBO J, V15, P6155
[6]   HIV-1 infection of non-dividing cells: evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import [J].
Fouchier, RAM ;
Meyer, BE ;
Simon, JHM ;
Fischer, U ;
Malim, MH .
EMBO JOURNAL, 1997, 16 (15) :4531-4539
[7]   Lentivirus-mediated transduction of islet grafts with interleukin 4 results in sustained gene expression and protection from insulitis [J].
Gallichan, WS ;
Kafri, T ;
Krahl, T ;
Verma, IM ;
Sarvetnick, N .
HUMAN GENE THERAPY, 1998, 9 (18) :2717-2726
[8]   Requirements for efficient production and transduction of human immunodeficiency virus type 1-based vectors [J].
Gasmi, M ;
Glynn, J ;
Jin, MJ ;
Jolly, DJ ;
Yee, JK ;
Chen, ST .
JOURNAL OF VIROLOGY, 1999, 73 (03) :1828-1834
[9]  
GRAF M, 2000, IN PRESS J VIROL
[10]   Construction, replication, and immunogenic properties of a Simian immunodeficiency virus expressing interleukin-2 [J].
Gundlach, BR ;
Linhart, H ;
Dittmer, U ;
Sopper, S ;
Reiprich, S ;
Fuchs, D ;
Fleckenstein, B ;
Hunsmann, G ;
StahlHennig, C ;
Uberla, K .
JOURNAL OF VIROLOGY, 1997, 71 (03) :2225-2232